Crescent Biopharma Inc 2026年季度报告

FORM 10-Q/AAmendment No. 1________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31, 2026OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _________ to _________Commission file number 001-36177________________________________ Crescent Biopharma, Inc. (Exact name of registrant as specified in its charter)________________________________ Cayman Islands06-1686563(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)300 Fifth AvenueWaltham,MA02451(Address of Principal Executive Offices)(Zip Code)Registrant’s telephone number, including area code:(617) 430-5595 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo☒ As of April 24, 2026, there were 27,571,935 of the issuer’s ordinary shares outstanding. Explanatory Note Crescent Biopharma, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment”) to its QuarterlyReport on Form 10-Q for the quarterly period ended March 31, 2026, which was originally filed with the Securities and ExchangeCommission (the “SEC”) on April 29, 2026 (the “Original Filing”). This Amendment is being filed to revise Part II “Item 5. OtherInformation” by adding disclosure regarding Rule 10b5-1 trading arrangements (as defined in Item 408(a) of Regulation S-K), whichwas inadvertently omitted from the Original Filing. In addition, as required by Rule 12b-15 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), newcertifications by the Company’s principal executive officer and principal financial officer are filed herewith as exhibits to thisAmendment, under Part II, Item 6 hereof, pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act. Because no financialstatements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. The Company is also not including newcertifications under Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) (Section 906 of the Sarbanes-Oxley Act of 2002), as no financial statements are being filed with this Amendment. Other than as expressly set forth herein, this Amendment does not, and does not purport to, amend, update or restate the information inthe Original Filing or reflect any events that have occurred after the date the Original Filing was made. Information not affected by thisAmendment remains unchanged and reflects the disclosures made at the time as of which the Original Filing was made. No changeshave been made to the financial statements of the Company as contained in the Original Filing. Accordingly, this Amendment shouldbe read together with the Original Filing and the Company’s other filings with the SEC. Part II - Other Information Item 5. Other Information (a) None. (b) None. (c) Trading ArrangementsOn February 25, 2026, each of (i) Joshua Brumm, our Chief Executive Officer and member of the Company’s Board of Directors, (ii) Jonathan McNeill, our Chief Operating Officer and President, (iii) Ellie Im, our Chief Medical Officer, (iv) Jan Pinkas, our ChiefScientific Officer, (v) Richard Scalzo, our Chief Financial Officer, (vi) Ryan Lynch, our Treasurer, Senior Vice President of Financeand Chief Accounting Officer, and (vii) Barbara Bispham Hale, our General Counsel and Corporate Secretary, adopted a Rule